In addition, a survival benefit of anti-PD-1/PD-L1 combinational therapy was mainly observed in specific tumor types, including NSCLC, SCLC, ESCC, melanoma and NPC. Here, PDCD1 is linked to esophageal squamous cell carcinoma.